- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04545580
Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB) (OVADER)
A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multi-center, Proof-of-concept Study to Assess the Efficacy and Safety of BAY 1817080 in Patients With Overactive Bladder (OAB) Over a 12-week Treatment Period
The aim of the study is to determine how well the drug BAY1817080 works in OAB patients with urgency urinary incontinence (UUI), defined as involuntary leakage of urine, accompanied or immediately preceded by a sudden compelling desire to void.
BAY1817080 is a new drug under development which blocks proteins expressed on the sensory nerves in the bladder. These nerves seem to overreact in OAB patients.
This study will test if the treatment with BAY1817080 will reduce the frequency of OAB symptoms. The frequency of OAB symptoms before the treatment and the frequency after 4, 8 and 12 weeks of treatment will be compared.
Another important objective of this study will be the assessment of BAY1817080 safety and tolerability in this patient population.
BAY1817080 will be compared to a "placebo". A placebo tablet looks like the study drug but does not have any medicine in it. Using a placebo helps to learn if the study drug works. Each participant is expected to take part in the study for about 5 months (around 20-22 weeks).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New South Wales
-
Botany, New South Wales, Australia, 2019
- Emeritus Research
-
-
Victoria
-
Camberwell, Victoria, Australia, 3124
- Emeritus Research
-
-
-
-
-
Innsbruck, Austria, 6020
- Medizinische Universität Innsbruck
-
-
Steiermark
-
Graz, Steiermark, Austria, 8036
- Medizinische Universität Graz
-
-
-
-
-
Benesov, Czechia, 256 01
- Afimed s.r.o
-
Cheb, Czechia, 350 02
- GYNEKOLOGIE CHEB s.r.o.
-
Olomouc, Czechia, 772 00
- G-Centrum Olomouc s.r.o. Dr. Skrivanek
-
Plzen, Czechia, 326 00
- Gyncare MUDr. Michael Švec s.r.o.
-
Praha 2, Czechia, 120 00
- Urocentrum Praha, s.r.o.
-
Praha 6, Czechia, 160 00
- Androgeos - private center of urology and andrology
-
Praha 8, Czechia, 180 00
- Fakultni nemocnice Bulovka
-
-
-
-
Nordrhein-Westfalen
-
Duisburg, Nordrhein-Westfalen, Germany, 47169
- Urologicum Duisburg - Praxis Walsum
-
Mettmann, Nordrhein-Westfalen, Germany, 40822
- Überörtliche Gemeinschaftspraxis "Urologie Neandertal"
-
-
Sachsen-Anhalt
-
Halle, Sachsen-Anhalt, Germany, 06132
- Praxis Hr. Dr. M. Markov
-
Lutherstadt Eisleben, Sachsen-Anhalt, Germany, 06295
- Urologicum
-
-
-
-
-
Christchurch, New Zealand, 8013
- Canterbury Urology Research Trust
-
Tauranga, New Zealand, 3112
- Tauranga Urology Research Limited
-
-
-
-
-
Krakow, Poland, 31-315
- Medico Praktyka Lekarska
-
Lublin, Poland, 20-632
- NZOZ NOVITA, Specjalistyczne Gabinety Lekarskie S.C
-
Myslowice, Poland, 41-400
- Centrum Urologiczne sp. z o.o.
-
Piaseczno, Poland, 05-500
- NZOZ Heureka
-
Skierniewice, Poland, 96-100
- Przychodnia Lekarska Eskulap
-
-
-
-
-
Lisboa, Portugal, 1649-035
- CHULN - Hospital Santa Maria
-
Porto, Portugal, 4200-319
- CHUSJ - Hospital Sao Joao
-
Porto, Portugal, 4050
- Centro Hospitalar Universitario do Porto
-
-
-
-
-
Singapore, Singapore, 229899
- KK Women's and Children's Hospital
-
-
-
-
-
Göteborg, Sweden, 411 36
- Göteborgs Urologmottagning
-
Solna, Sweden, 170 73
- Urogyn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
at screening:
- Adults ≥ 18 years of age at the time of signing the informed consent
- Have "wet" OAB symptoms (urgency, frequency and urinary incontinence) for ≥ 3 months prior to screening visit
- Women of childbearing potential (WOCBP) must agree to use acceptable effective or highly effective contraceptive methods
- Capable of giving signed informed consent
- Willing and able to complete the electronic bladder diary and questionnaires
at baseline (to be checked at V3, prior to randomization):
- Completion of all 3 days of 3-day electronic bladder diary during run-in phase
- Compliance of ≥80% with intake of study intervention during run-in
- Frequency of micturition on average ≥ 8 episodes/24 hours during the run-in phase according to 3-day electronic bladder diary
- Frequency of urgency urinary incontinence on average ≥ 1 episode/24 hours during the run-in phase according to 3-day electronic bladder diary
Exclusion Criteria:
- Polyuria known or based on the clinical evidence during the run-in phase recorded in the 3-day electronic bladder diary and the investigator´s clinical judgement
- Significant stress incontinence or mixed stress/urgency incontinence
- Post-void residual volume (PVR) > 150 mL at Visit 1 or at Visit 3
- In need of catheterization (indwelling or intermittent)
- Clinically significant urinary outflow obstruction
- Previous pelvic radiation, or previous or current malignant disease of pelvic organs
- Neurogenic bladder
- Bladder pain syndrome/interstitial cystitis
- Recurrent and/or symptomatic bladder stones
- Current symptomatic or recent (within 30 days prior to Visit 1), or recurrent (2 or more infections within 6 months, or > 3 infections within 12 months) urinary tract infection
- Unexplained macro- or micro-hematuria
- Diabetes insipidus
- Diabetes mellitus with inadequate glycemic control as indicated by HbA1C result of > 8% at screening
- Clinically significant cardiovascular or cerebrovascular disease
- Systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg
- Clinically significant abnormal electrocardiogram (ECG) at screening
- Moderate-to-severe hepatic impairment defined as Child-Pugh Class B or C
- Laboratory values outside the inclusion range (as specified in the laboratory manual and in the reports from the central laboratory) before start of study intervention, and considered clinically relevant
At screening:
- ALT above 2xULN OR
- AST above 2xULN OR
- total bilirubin greater than ULN OR
- AP above 2x ULN OR
- INR greater than ULN (unless on vitamin K antagonist treatment) OR
- Positive hepatitis B virus surface antigen (HBsAg) OR
- Positive hepatitis C virus antibodies (anti-HCV) and detection of mRNA (HCV-mRNA, only tested if hepatitis C virus antibodies were detected)
- Severe renal impairment as defined by estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m^2 calculated by Modification of Diet in Renal Disease (MDRD) formula
- Any other diseases or conditions that according to the investigator can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study intervention (e.g., excessively low body weight, Chronic bowel disease, Crohn's disease and ulcerative colitis)
- Any severe or unstable diseases or medical conditions including psychiatric disorders that might interfere with the conduct of the study, or could jeopardize the safety of the participant, or the interpretation of the results
- History of major depression within 2 years prior to screening, or a history of other major psychiatric disorder at any time (e.g., schizophrenia, bipolar disorder)
- Concurrent malignancy or history of cancer (except for adequately treated basal cell or squamous cell carcinoma of the skin) within the last 5 years prior to screening
Intake of prohibited medication due to potential drug-drug interaction Use of other treatments that might interfere with the conduct of the study or the interpretation of the results e.g.
- a) use of any drug treatment after start of study intervention intended for the OAB/UI symptoms other than the study intervention
- b) neuromodulation therapy and intravesical treatment - less than 12 months prior to screening or at any time during the study
- c) use of any treatment intended for other conditions but which can affect urinary bladder function during the study
- d) Non-drug treatment (e.g. physical treatment or acupuncture): permitted only if initiated ≥4 weeks prior to Screening and planned to be continued during the study)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Treatment period: Placebo
This arm consists of participants who complete the run-in period, and are still eligible, according to all in- and exclusion criteria for diagnosis of OAB with UUI based on bladder diary baseline data.
Participants will be randomized to 12 weeks of double-blind treatment with matching placebo.
|
Matching placebo for BAY1817080, will be taken twice daily orally as tablet(s)
|
Experimental: Treatment period: BAY1817080
This arm consists of participants who complete the run-in period, and are still eligible, according to all in- and exclusion criteria for diagnosis of OAB with UUI based on bladder diary baseline data.
Participants will be randomized to 12 weeks of double-blind treatment with BAY1817080.
|
BAY1817080 will be taken twice daily orally as tablet(s)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Average change from baseline over Week 4, 8 and 12 (end of treatment [EoT]) in mean number of urgency urinary incontinence (UUI) episodes/24 hours based on electronic bladder diary
Time Frame: From baseline up to 12 weeks
|
From baseline up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline to Week 12 (EoT) based on electronic bladder diary in mean number of UUI episodes/24 hours
Time Frame: From baseline up to 12 weeks
|
From baseline up to 12 weeks
|
Change from baseline to Week 12 (EoT) based on electronic bladder diary in mean number of urinary incontinence (UI) episodes/24 hours
Time Frame: From baseline up to 12 weeks
|
From baseline up to 12 weeks
|
Change from baseline to Week 12 (EoT) based on electronic bladder diary in mean number of micturition episodes/24 hours
Time Frame: From baseline up to 12 weeks
|
From baseline up to 12 weeks
|
Change from baseline to Week 12 (EoT) based on electronic bladder diary in mean number of urgency episodes (Grade 3 or 4)/24 hours
Time Frame: From baseline up to 12 weeks
|
From baseline up to 12 weeks
|
Change from baseline to Week 12 (EoT) based on electronic bladder diary in mean number of nocturia episodes/24 hours
Time Frame: From baseline up to 12 weeks
|
From baseline up to 12 weeks
|
Change from baseline to Week 12 (EoT) based on electronic bladder diary in mean volume voided per micturition
Time Frame: From baseline up to 12 weeks
|
From baseline up to 12 weeks
|
Incidence of adverse events
Time Frame: From the start of study intervention (at start of run-in) until the follow-up visit (up to 18 weeks)
|
From the start of study intervention (at start of run-in) until the follow-up visit (up to 18 weeks)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19733
- 2019-002575-34 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access.
As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.
Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overactive Bladder
-
Ankara Yildirim Beyazıt UniversityCompletedOveractive Bladder | Overactive Detrusor | Overactive Bladder SyndromeTurkey
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOveractive Bladder (OAB)United States, Canada, Germany, Korea, Republic of, Spain, Turkey, Taiwan, Italy, Slovakia, Denmark, South Africa, United Kingdom, Mexico, Sweden, Norway
-
Medstar Health Research InstituteColumbia University; University of Michigan; University of New Mexico; Methodist...Terminated
-
Astellas Pharma Global Development, Inc.CompletedOveractive Bladder (OAB)United States, Canada
-
Merck Sharp & Dohme LLCTerminatedOveractive Bladder | Overactive Urinary Bladder
-
Loyola UniversityAstellas Pharma IncCompletedOveractive Bladder SyndromeUnited States
-
Beijing Pins Medical Co., LtdUnknown
-
Maastricht University Medical CenterUnknownLower Urinary Tract Symptoms | Overactive Bladder SyndromeNetherlands
-
Pamukkale UniversityCompletedElectrical Stimulation | Idiopathic Overactive Bladder | Bladder TrainingTurkey
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States